Senores Pharma.

Why is Senores Pharmaceuticals Ltd falling/rising?

As of 02-Jul, Senores Pharmaceuticals Ltd's stock price has risen to 1,335.85, up 1.5%, driven by strong financial performance and significant outperformance against the Sensex. Key factors include a 71.70% growth in net sales, an 80.72% increase in profit after tax, and rising institutional investor confidence.

As of 02-Jul, Senores Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 1,335.85, reflecting an increase of 19.8 (1.5%). This upward movement can be attributed to several positive factors highlighted in the data. <BR><BR>The stock has significantly outperformed the benchmark Sensex, with a weekly return of +5.27% compared to the Sensex's +0.52%, and a remarkable annual return of +130.12% against the Sensex's -7.08%. Additionally, the company has shown strong financial performance, with net sales growing at an annual rate of 71.70% and operating profit increasing by 108.34%. The latest six months' profit after tax (PAT) has grown by 80.72%, reaching Rs 63.27 crore, and the company achieved its highest quarterly net sales at Rs 175.19 crore.<BR><BR>Moreover, the stock is trading above its moving averages across various time frames, indicating a positive trend. Institutional investor participation has also increased, with a 0.59% rise in their stake, suggesting confidence in the company's fundamentals. Despite a slight decline in delivery volume, the overall liquidity remains sufficient for trading.<BR><BR>These factors collectively contribute to the stock's rising price, reflecting strong market confidence and robust company performance.

Which are the latest news on Senores Pharma.?

Should I buy, sell or hold Senores Pharmaceuticals Ltd?

What does Senores Pharma. do?

Senores Pharmaceuticals Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, recently reporting net sales of 175 Cr and a net profit of 32 Cr for the quarter ending March 2026. The company was incorporated in 2017 and became a public limited company in 2023.

Overview: <BR>Senores Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Senores Pharmaceuticals Ltd was originally incorporated as "Senores Pharmaceuticals Private Limited" in 2017. The company transitioned to a Public Limited Company and changed its name to "Senores Pharmaceuticals Limited" in 2023. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 175 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 32 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 5,189 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 45.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.20 <BR>Return on Equity: 12.36% <BR>Price to Book: 5.40 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Senores Pharma.?

As of 10th June, Senores Pharmaceuticals Ltd has a market capitalization of 5,189.00 Cr, with recent net sales of 645.89 Cr and net profit of 115.38 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Senores Pharmaceuticals Ltd has a market capitalization of 5,189.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 645.89 Cr, while the sum of Net Profit for the same period is 115.38 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 786.18 Cr, and Total Assets are valued at 1,208.19 Cr.

Who are the peers of the Senores Pharma.?

Senores Pharma's peers include Sanofi India, SPARC, FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., and Advanced Enzyme. Senores Pharma leads in 1-year returns at 117.05%, while Sanofi India has the lowest at -48.68%.

Peers: The peers of Senores Pharma. are Sanofi India, SPARC, FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., Advanced Enzyme.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India and Guj. Themis Bio., while Good management risk is found at Innova Captab. Average management risk is present at SPARC, FDC, Aarti Pharma, Bliss GVS Pharma, and Advanced Enzyme, and the rest. Below Average management risk is noted at Orchid Pharma. For Growth, Excellent growth is seen at Senores Pharma. and SPARC, while Average growth is found at Innova Captab, and the rest. Below Average growth is observed at Sanofi India, FDC, Aarti Pharma, Bliss GVS Pharma, Orchid Pharma, Guj. Themis Bio., and Advanced Enzyme. Excellent capital structure is noted at Sanofi India, FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Guj. Themis Bio., and Advanced Enzyme, while Good capital structure is found at Senores Pharma., and Below Average capital structure is observed at Orchid Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 117.05%, while the lowest is Sanofi India at -48.68%. Senores Pharma.'s return significantly outperforms all peers. Additionally, the six-month return is negative for Sanofi India, FDC, Aarti Pharma, and Guj. Themis Bio.

Are Senores Pharmaceuticals Ltd latest results good or bad?

Senores Pharmaceuticals Ltd's Q4 FY26 results show strong revenue and net profit growth, with a net profit increase of 77.29% year-on-year and net sales up 53.39%. However, declining operating margins and rising interest costs raise concerns about future profitability sustainability.

Senores Pharmaceuticals Ltd's latest results for Q4 FY26 can be considered quite strong in terms of revenue and net profit growth. The company reported a net profit of ₹31.61 crores, which is a remarkable increase of 77.29% year-on-year. Additionally, net sales grew by 53.39% compared to the same quarter last year, reaching ₹175.19 crores. This marks the seventh consecutive quarter of sequential revenue growth, indicating consistent operational momentum and market share gains.<BR><BR>However, there are some concerns regarding profitability metrics. The operating margin (excluding other income) decreased to 27.11% from 29.48% in the previous quarter, which raises questions about the sustainability of the company's pricing power and cost management. Furthermore, the increase in interest costs to ₹8.46 crores, the highest on record, could impact future profitability.<BR><BR>Overall, while the revenue and profit growth figures are impressive, the margin compression and rising costs suggest that investors should monitor the company's ability to maintain its growth trajectory and profitability in the coming quarters.

When is the next results date for Senores Pharmaceuticals Ltd?

The next results date for Senores Pharmaceuticals Ltd is 20 January 2026.

The next results date for Senores Pharmaceuticals Ltd is scheduled for 20 January 2026.

How has been the historical performance of Senores Pharma.?

Senores Pharma experienced significant growth from March 2024 to March 2025, with net sales rising from 214.52 Cr to 398.25 Cr and profit after tax increasing from 32.71 Cr to 58.34 Cr, despite higher raw material and employee costs. Total assets and liabilities both grew to 1,208.19 Cr, while cash flow from financing activities improved significantly.

Answer:<BR>The historical performance of Senores Pharma shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Senores Pharma's net sales increased substantially from 214.52 Cr in March 2024 to 398.25 Cr in March 2025, reflecting strong operational growth. Total operating income followed the same trend, rising to 398.25 Cr from 214.52 Cr. However, raw material costs surged to 91.64 Cr from 31.96 Cr, and employee costs also rose to 60.37 Cr from 35.46 Cr, contributing to a total expenditure of 308.55 Cr, up from 172.92 Cr. Operating profit (PBDIT) improved significantly to 108.96 Cr from 44.42 Cr, with profit before tax reaching 70.57 Cr compared to 24.95 Cr the previous year. Profit after tax also saw an increase to 58.34 Cr from 32.71 Cr. The company's total assets grew to 1,208.19 Cr from 606.92 Cr, while total liabilities increased to 1,208.19 Cr from 606.92 Cr as well. Cash flow from operating activities remained negative at -45.00 Cr, but cash flow from financing activities turned positive at 573.00 Cr, leading to a net cash inflow of 97.00 Cr, up from 7.00 Cr. Overall, Senores Pharma demonstrated robust growth in revenue and profitability, alongside increased asset and liability levels.

Is Senores Pharma. overvalued or undervalued?

As of September 18, 2025, Senores Pharma is considered very expensive and overvalued with a PE ratio of 56.49 and lower returns compared to peers, despite a year-to-date stock performance of 25.84% against the Sensex's 6.24%.

As of 18 September 2025, the valuation grade for Senores Pharma has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued, with a PE ratio of 56.49, an EV to EBIT of 44.43, and an EV to EBITDA of 36.09. These ratios are considerably higher than its peers, such as Sun Pharma, which has a PE ratio of 34.46 and an EV to EBITDA of 23.34, and Cipla, which boasts a more attractive PE ratio of 23.65 and an EV to EBITDA of 16.67.<BR><BR>In comparison to its industry, Senores Pharma's financial metrics suggest that it is not only overvalued but also lacks competitive returns, as evidenced by its ROE of 7.45% and ROCE of 10.18%. While the stock has outperformed the Sensex year-to-date with a return of 25.84% compared to the Sensex's 6.24%, the overall valuation metrics indicate that investors may be paying a premium that is not justified by the company's financial performance.

What is the technical trend for Senores Pharma.?

As of March 10, 2025, Senores Pharma's technical trend is neutral with no strong signals, as indicators like MACD and RSI show a sideways movement, despite recent outperformance against the Sensex.

As of 10 March 2025, the technical trend for Senores Pharma has changed to sideways. The current technical stance is neutral, with no strong bullish or bearish signals evident. The MACD, RSI, and other indicators do not provide clear directionality on the weekly or monthly time frames. The Dow Theory indicates no trend on the weekly and monthly levels, and the On-Balance Volume (OBV) also shows no trend. The stock's recent performance has outpaced the Sensex over the past week and month, but the year-to-date return is negative, suggesting mixed sentiment. Overall, the lack of definitive indicators keeps the outlook neutral.

Who are the top shareholders of the Senores Pharma.?

The top shareholders of Senores Pharma include promoter Swapnil Jatin Shah with 7.72%, Aditya Birla Sun Life Insurance Company Limited at 3.71%, mutual funds with 3.23%, foreign institutional investors holding 4.17%, and individual investors collectively owning 31.43%.

The top shareholders of Senores Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Swapnil Jatin Shah, owning 7.72% of the company. Additionally, Aditya Birla Sun Life Insurance Company Limited is the highest public shareholder, holding 3.71%. The company also has mutual funds holding 3.23% across five schemes and foreign institutional investors (FIIs) holding 4.17% through 21 different entities. Individual investors collectively hold 31.43% of the shares.

Has Senores Pharma. declared dividend?

No Dividend History Available